David Traylor David Traylor

David Traylor is Senior Managing Director at Golden Eagle Partners, a firm he founded in 2012 to advise life science companies. After advising on various transactions in the life science sector, he took an interest in the cannabis sector and started advising cannabis companies in 2013. In 2014, he joined Surna, Inc. (OTC:SRNA) as Chief Business Officer. After close to a year stint at Surna, Mr. Traylor re-founded Golden Eagle Partners to provide his knowledge to companies across the cannabis sector. Before Golden Eagle Partners, Mr. Traylor served at leading investment banking firms including Pacific Growth Equities (which later became Wedbush), Caris & Company and Headwaters MB (which later became Capstone Headwaters). During his banking tenures he has advised private and public biotechnology and medical device companies in various transactions including IPOs, public offerings, private offerings, mergers and acquisitions totaling over $500 million in value.

Before investment banking, Mr. Traylor spent fifteen years in diverse operational roles in biotechnology companies, from research and development to business development, manufacturing, program management and senior management. He began his career in biotechnology, with a position in bioprocess manufacturing at Synergen (acquired by Amgen), and then moved into R&D and process development positions at Somatogen, a company pursuing a recombinant blood substitute. After Somatogen (acquired by Baxter), he led the management of programs and development initiatives at Affymetrix (acquired by Thermo Fisher), the leading innovator in microarray technology. Mr. Traylor began his business development career at Deltagen then moved over the lead the U.S. operations for atugen AG (acquired by Silence Therapeutics), a Berlin-based functional genomics company. At Bioseek (acquired by Asterand), David led the business development efforts for one of the first systems biology companies.

In 1988, Mr. Traylor was one of five Colorado players selected to play for the Denver Rifles in the American Lacrosse League (ALL) – the first U.S. professional field lacrosse league. Mr. Traylor is parlaying his athletic background and knowledge in cannabis as a valuable member of Athletes for Care. He received B.A. degrees from the University of Colorado, Boulder in Biochemistry and Molecular, Cellular and Developmental Biology and an M.B.A. from the Leeds School of Business at the University of Colorado-Boulder. He is also the inventor on three issued U.S. patents. Mr. Traylor is a registered representative and has passed the FINRA Series 7, 63 and 66 examinations.

David Traylor is registered in the following states: CA, CO, CT, FL, IL, MA, NV, NJ, NY, OR, PR, TX, WA.

David can be reached via the Contact Page or Linkedin.

Matt Daugherty

Matthew Daugherty is a Senior Vice President with Golden Eagle Partners working to source, manage and close equity and debt transactions. Matthew has over 18 years of experience working across the capital markets industry with a strong skill set in due diligence and analytics, with an appreciation of maintaining a reliable, results-defining, professional reputation in the alternative investment sector.

Prior to joining Golden Eagle Partners, he was with Somerset Capital, a private capital firm that employs industry-specific skillsets to make strategic investments in distressed and turnaround situations as well as merger and direct investment in private and pre-public companies. He was tasked with sourcing deals for potential RTO transactions. Then while at AR2 Capital and Alpha Strategies he provided consulting services for accredited investors and other investment advisers on a variety of alternative investments including hedge funds, private equity, real estate, and venture capital. He also sat on the fixed income trading desks for both Continental Investor Services Inc., and First Southwest Company. Where he was a fixed income sales and trading and Institutional Sales Middle Markets Advisor. He began his financial career as an analyst then as a senior analyst with both Standard and Poor’s and Oppenheimer funds for both traditional and alternative investments. Mr. Daugherty received a Bachelor of Arts in Political Science from University of Colorado at Boulder. Mr. Daugherty is a registered representative and has passed the FINRA Series 7, 63 and 65 examinations.

Matt Daugherty is registered in the following state: CO.

Consultants and Advisors

Ron Kammerzell

Ron is currently an independent consultant specializing in regulatory policy and governmental affairs. In August 2017, Ron retired from the Colorado Department of Revenue after more than 25 years of service. Prior to his retirement from the Department, Ron served as the Senior Director of Enforcement for nearly 5 years where he had management oversight responsibilities over five divisions including Liquor/Tobacco Enforcement, Gaming, Racing, Auto Industry and Marijuana Enforcement for the Colorado Department of Revenue. Prior to his appointment as the Senior Director of Enforcement in October 2012, Ron spent nearly 20 years with the Division of Gaming regulating the casino industry in Colorado, including 7 years as the Division Director. Ron also served as the Director of Security for the Colorado Lottery and began his state career with the Colorado Office of the State Auditor. Over the years, Ron has gained extensive experience in complex criminal and financial investigations, auditing, internal controls, regulatory law, public policy and public administration. Several of Ron’s most notable accomplishments at the Department were the successful implementation of Amendment 50 expanding betting limits, hours of operation and games offered by the regulated casino industry in Colorado, implementation of Amendment 64 legalizing retail marijuana in the State, and implementation of SB 17-197 expanding the sale of wine, spirits and full-strength beer at grocery stores in Colorado. Ron was appointed by the Governor to the Amendment 64 Implementation Task Force and co-chaired the Regulatory Framework Working Group establishing the initial rules for retail marijuana in Colorado. Ron was intimately involved in the implementation of Amendment 64 and setting marijuana regulatory policy for the Department of Revenue for nearly 5 years. Today, he is widely recognized as an expert in the implementation of marijuana regulatory policy in North America and internationally. Ron has recently been active in the evolving marijuana policy in Connecticut, New Hampshire and Oklahoma.

Ron is a native of Colorado. He graduated from Colorado State University with a BSBA in Finance and Real Estate, with a minor in Economics. Ron is a Colorado POST Certified peace officer.

Graeme Martin

Currently dividing his time between London, UK and the San Francisco Bay Area, Graeme Martin trained as a pharmacologist at The University of Bath, UK and subsequently at University College London, where he gained his Ph.D.. He began his Pharma R&D career at The Wellcome Research Laboratories in Beckenham, Kent, UK, working initially on dopaminergic control of cardiac function in the Research Division of Nobel Laureate, Professor Sir John Vane, whose own research unravelled the mechanisms of action of aspirin and provided the first deep understanding of prostaglandin biology. Subsequently, Martin researched the therapeutic possibilities of modulating monoaminergic reuptake transporters under the tutelage of Dr Laurence Garland and Professor Ullrich Trendelenburg at the University of Wurzburg. A growing interest in G-protein coupled receptors (GPCRs) as drug targets then lead to a period in the laboratory of Nobel Laureate Professor Sir James Black, inventor of beta-blockers and histamine H2 receptor antagonists. From 1993 to 2008, Martin was the Chair of the IUPHAR Sub-Committee for Serotonin Receptor Classification and was instrumental in establishing the unifying classification nomenclature for GPCRs used today. His research led to the development of four serotonin receptor sub-type selective drugs that were advanced into human clinical trials. One of these drugs, Zolmitriptan, has been marketed since 1997 as Zomig© for the acute treatment of migraine.
Following the acquisition of Wellcome by Glaxo in 1995, Martin moved to the USA to head the Molecular Pharmacology Department of a newly formed Neurobiology Unit of Roche Biosciences. Here, his team explored the potential for enhancing drug selectivity via biased, or cell-selective, signaling. In 2003, he joined Takeda’s newly formed venture group in Palo Alto, assuming responsibility for the unit as President & CEO in 2003. In April 2017, Martin formed HatchBox Bioconsulting, LLC in order to dedicate more time to support early stage life science innovation.